KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Twist Bioscience (TWST) Liabilities and Shareholders Equity (2017 - 2025)

Historic Liabilities and Shareholders Equity for Twist Bioscience (TWST) over the last 9 years, with Q4 2025 value amounting to $638.1 million.

  • Twist Bioscience's Liabilities and Shareholders Equity rose 484.82% to $638.1 million in Q4 2025 from the same period last year, while for Dec 2025 it was $2.5 billion, marking a year-over-year decrease of 174.35%. This contributed to the annual value of $641.9 million for FY2025, which is 448.27% up from last year.
  • According to the latest figures from Q4 2025, Twist Bioscience's Liabilities and Shareholders Equity is $638.1 million, which was up 484.82% from $641.9 million recorded in Q3 2025.
  • Over the past 5 years, Twist Bioscience's Liabilities and Shareholders Equity peaked at $1.0 billion during Q1 2022, and registered a low of $595.6 million during Q1 2025.
  • In the last 5 years, Twist Bioscience's Liabilities and Shareholders Equity had a median value of $714.1 million in 2021 and averaged $751.0 million.
  • In the last 5 years, Twist Bioscience's Liabilities and Shareholders Equity skyrocketed by 10912.24% in 2021 and then tumbled by 2125.23% in 2024.
  • Over the past 5 years, Twist Bioscience's Liabilities and Shareholders Equity (Quarter) stood at $786.2 million in 2021, then rose by 15.75% to $910.0 million in 2022, then dropped by 19.47% to $732.8 million in 2023, then decreased by 16.95% to $608.6 million in 2024, then increased by 4.85% to $638.1 million in 2025.
  • Its Liabilities and Shareholders Equity was $638.1 million in Q4 2025, compared to $641.9 million in Q3 2025 and $643.6 million in Q2 2025.